Drug Type Autologous CAR-T |
Synonyms 4-1BB-modified CAR CD8+ central memory and CD4+ T lymphocyte therapy - Juno Therapeutics, JCAR 014 |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic lymphocytic leukaemia refractory | Phase 2 | US | 22 May 2013 | |
Diffuse large B-cell lymphoma recurrent | Phase 2 | US | 22 May 2013 | |
Diffuse large B-cell lymphoma refractory | Phase 2 | US | 22 May 2013 | |
Mantle cell lymphoma recurrent | Phase 2 | US | 22 May 2013 | |
Mantle cell lymphoma refractory | Phase 2 | US | 22 May 2013 | |
Recurrent Adult Acute Lymphoblastic Leukemia | Phase 2 | US | 22 May 2013 | |
Recurrent Chronic Lymphoid Leukemia | Phase 2 | US | 22 May 2013 | |
Refractory acute lymphoid leukemia | Phase 2 | US | 22 May 2013 | |
Refractory Small Lymphocytic Lymphoma | Phase 2 | US | 22 May 2013 | |
B-cell lymphoma recurrent | Phase 1 | US | 03 Nov 2017 |
NCT01865617 (Pubmed) Manual | Phase 1/2 | Refractory B Acute Lymphoblastic Leukemia MRD-negative | 53 | Chemotherapy+JCAR-014 (MRD-negative CR) | krkefwfkmx(hboozqjxlv) = iyapvdhsok zcjkjcobvf (eiffhhzqaz ) View more | Positive | 11 Apr 2019 |
Chemotherapy+JCAR-014 (not MRD-negative CR) | krkefwfkmx(hboozqjxlv) = mwumiefpnx zcjkjcobvf (eiffhhzqaz ) View more | ||||||
NCT02706405 (ASH2018) Manual | Phase 1 | 15 | wngzilbfkt(pumavzxlod) = 5 pts (38%) developed CRS (2 grade 1, 2 grade 2, and 1 grade 4) and one (8%) developed grade 1 neurotoxicity. jbhsupirtu (dvrngbsfhh ) | Positive | 29 Nov 2018 |